Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
Posted on August 19, 2010 at 5:38 am by admin · Permalink
· Leave a comment
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Shareholder, Trubion Pharmaceuticals, United States · Tagged with: Biosolutions, Board of directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Shareholder, Trubion Pharmaceuticals, United States · Tagged with: Biosolutions, Board of directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals